Natera

Revenue Cycle Analyst, Prior Authorization

United States

Natera Logo
Not SpecifiedCompensation
Junior (1 to 2 years)Experience Level
Full TimeJob Type
UnknownVisa
Healthcare, Genetic TestingIndustries

Requirements

Candidates should possess a Bachelor's degree in business or a healthcare-related field, or equivalent professional experience, with at least 2-3 years of experience in medical billing and insurance collections. Extensive knowledge in revenue cycle operations, particularly with a focus on prior authorization, is required. Strong analytical skills, including proficiency with data analysis tools like Excel or PowerBI, are also necessary.

Responsibilities

The Revenue Cycle Analyst, Prior Authorization will serve as a source of knowledge for the designated revenue cycle function, performing analysis to identify trends and prioritize performance improvement initiatives. They will establish relationships with other departments, conduct complex data analysis, track prior authorization outcomes, participate in weekly meetings to review metrics, research payer policies, coordinate with management, support strategic goals, assist with implementation plans, educate teams on performance improvement, and seek out new technologies to guide improvement opportunities.

Skills

Data Analysis
Revenue Cycle Operations
Prior Authorization
Payer Policies
Data Interpretation
Billing and Coding
Performance Improvement

Natera

Genetic testing and diagnostics solutions provider

About Natera

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology is cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT, along with genetic counseling services. The company's goal is to improve patient care and health outcomes through accurate genetic testing.

Key Metrics

Austin, TexasHeadquarters
2004Year Founded
$149.9MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
1,001-5,000Employees

Benefits

Flexible medical plans
Investment options
Time off
Workplace perks

Risks

Hindenburg report accuses Natera of deceptive sales practices, risking legal challenges.
New Prospera Heart features may face slow adoption by healthcare providers.
Fetal RhD NIPT demand may drop post-RhIg shortage, affecting future sales.

Differentiation

Natera's Signatera test offers personalized ctDNA analysis for cancer patients.
Prospera Heart test uses unique Donor Quantity Score for transplant rejection detection.
Panorama NIPT test is a leader in non-invasive prenatal testing with 2 million tests.

Upsides

Increased adoption of liquid biopsy techniques boosts demand for Natera's cfDNA tests.
AI integration enhances accuracy and speed of Natera's cfDNA analysis.
Growing personalized medicine trend aligns with Natera's customized genetic tests.

Land your dream remote job 3x faster with AI